{
    "id": "6025d88c1cb411341a0000b6",
    "question": "Is vocimagene amiretrorepvec effective for glioblastoma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine the effectiveness of vocimagene amiretrorepvec for glioblastoma, I need to consider what vocimagene amiretrorepvec is and its mechanism of action. Vocimagene amiretrorepvec is a viral vector-based immunotherapy that encodes for the amiretrorep peptide, which is a fusion of the anti-cancer peptides Tumor-Associated Antigen (TAA) and the immunostimulatory peptide ISCOMM. This approach aims to stimulate an immune response against tumor cells expressing the TAA peptide. Glioblastoma is a type of brain cancer that is resistant to current treatments and has a poor prognosis. Given the nature of glioblastoma, immunotherapies that can stimulate an anti-tumor immune response are of great interest. The effectiveness of vocimagene amiretrorepvec for glioblastoma would depend on its ability to selectively target and activate immune cells to recognize and attack glioblastoma cells expressing the TAA peptide. As of my knowledge cutoff, there is limited information available on the clinical efficacy of vocimagene amiretrorepvec in treating glioblastoma. However, based on the underlying mechanism of action, it is plausible that vocimagene amiretrorepvec could be effective in stimulating an immune response against glioblastoma cells expressing the TAA peptide. Therefore, I will choose the answer based on this reasoning.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 32.04179501533508
}